Monographie - Clonazepam - Stabilis 4.0

Siste oppdatering :
05/12/2025

Antiepileptika

Clonazepam

Injeksjon

Mikstur

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Kjemisk struktur

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Clonazepamum	Polen
Kriadex	Mexico
Ravotril	Chile
Rivotril	Colombia, De forente arabiske emirater, Frankrike, Nederland, New Zealand, Polen, Spania, Sveits, Tyskland, Ungarn

Referanser

Injeksjon

Referanser : Clonazepam

	Type	publikasjon
939	Journal	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1189	Journal	Nation RL, Hackett LP, Dusci LJ. Uptake of clonazepam by plastic intravenous infusion bags and administration sets. Am J Hosp Pharm 1983 ; 40: 1692-1693.
1246	Journal	Hooymans PM, Janknegt R, Lohman JJHM. Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings. Pharm Weekbl [Sci] 1990 ; 12: 188-189.
1508	Journal	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2115	Journal	Schneider JJ, Good Ph, Ravenscroft PJ,. Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. J Pain Symptom Manage 2006 ; 31, 6: 563-567.
2217	Journal	Guchelaar H.J, Hartog M.E. De stabiliteit van clonazepaminjectievloeistof. Ziekenhuisfarmacie 1997 ; 13, 1: 21-23.
3184	Labratorium	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005
3617	Labratorium	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3728	Journal	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3823	Journal	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3976	Journal	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4867	plakat	Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al. Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 2024
4972	Labratorium	RIVOTRIL 1 mg/1 ml, solution à diluer injectable en ampoules - Résumé des caractéristiques du produit. CHEPLAPHARM ARZNEIMITTEL GMBH 2025

Mentions Légales